NCT07217990 (NoCUT-BC) is a Phase 1, PHASE2 clinical trial of Neoadjuvant Chemotherapy in Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

Who is sponsoring NCT07217990?

NCT07217990 is sponsored by Ohio State University Comprehensive Cancer Center.

What drugs are being tested in NCT07217990?

Interventions in NCT07217990: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection.

What condition does NCT07217990 study?

NCT07217990 studies Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer.

Is NCT07217990 still recruiting?

NCT07217990 is currently not yet recruiting. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT07217990: NoCUT-BC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Not yet recruiting Phase 1, PHASE2 Last updated 17 February 2026

What this trial tests

Phase 1, PHASE2 trial testing Neoadjuvant Chemotherapy in Breast Cancer in 84 participants. Not yet recruiting.

Timeline

15 April 2026

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	84
Start date	15 April 2026
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

Neoadjuvant Chemotherapy — full drug profile →
Radiation Therapy — full drug profile →
MRI — full drug profile →
Breast Cancer Surgery
Biopsy — full drug profile →
Biospecimen collection — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →
Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Breast Cancer or HER2-positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neoadjuvant Chemotherapy

Trials testing the same drug.

NCT07413146 — Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Lab · NA · not yet recruiting
NCT07383818 — Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST · Phase 2 · recruiting
NCT07202819 — Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy · NA · recruiting
NCT06977893 — Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Paralle · Phase 3 · recruiting
NCT06878222 — Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC · Phase 2 · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting
NCT07320664 — Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07217990 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07217990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing